Smith & Nephew’s Q1 16 results (trading update) came in marginally below analysts’ expectation (sales of $1.14bn vs. consensus estimate of $1.17bn). The revenue growth of 3% was a function of underlying growth of 4%, acquisition benefits of 2% and currency headwinds of 3%. Franchise-wise, the robust performance of sports medicine, knee/hip implants and advanced wound devices was negated to some extent by the underperformance of trauma & extremities and advanced wound bioac
05 Jul 2016
Recon and sports medicine shine amid weak China and the Gulf
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Recon and sports medicine shine amid weak China and the Gulf
Smith & Nephew plc (SN:LON) | 973 120.7 1.3% | Mkt Cap: 8,507m
- Published:
05 Jul 2016 -
Author:
Jyoti Prakash -
Pages:
3
Smith & Nephew’s Q1 16 results (trading update) came in marginally below analysts’ expectation (sales of $1.14bn vs. consensus estimate of $1.17bn). The revenue growth of 3% was a function of underlying growth of 4%, acquisition benefits of 2% and currency headwinds of 3%. Franchise-wise, the robust performance of sports medicine, knee/hip implants and advanced wound devices was negated to some extent by the underperformance of trauma & extremities and advanced wound bioac